Underuse of Catheter Ablation as First-Line Therapy for Supraventricular Tachycardia.
catheter ablation
drug therapy
logistic models
quality of life
supraventricular tachycardia
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
07 06 2022
07 06 2022
Historique:
pubmed:
4
6
2022
medline:
18
6
2022
entrez:
3
6
2022
Statut:
ppublish
Résumé
Background Catheter ablation (CA) is a safe, effective, cost-effective technique and may be considered a first-line strategy for the treatment of symptomatic supraventricular tachycardias (SVT). Despite the high prospect of cure and the recommendations of international guidelines in considering CA as a first-line treatment strategy, the average time between diagnosis and the procedure may be long. The present study aims to evaluate predictors related to non-referral for CA as first-line treatment in patients with SVT. Methods and Results The model was derived from a retrospective cohort of patients with SVT or ventricular pre-excitation referred for CA in a tertiary center. Clinical and demographical features were used as independent variables and non-referral for CA as first-line treatment the dependent variable in a stepwise logistic regression analysis. Among 20 clinical-demographic variables from 350 patients, 10 were included in initial logistic regression analysis: age, women, presence of pre-excitation on ECG, palpitation, dyspnea and chest discomfort, number of antiarrhythmic drugs before ablation, number of concomitant symptoms, symptoms' duration and evaluations in the emergency room due to SVT. After multivariable adjusted analysis, age (odds ratio [OR], 1.2; 95% CI 1.01-1.32;
Identifiants
pubmed: 35656985
doi: 10.1161/JAHA.121.022648
pmc: PMC9238702
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e022648Références
J Interv Card Electrophysiol. 2007 Sep;19(3):179-85
pubmed: 17823861
BMC Med Inform Decis Mak. 2016 Nov 3;16(1):138
pubmed: 27809908
Herzschrittmacherther Elektrophysiol. 2009 Apr;20(1):33-8
pubmed: 19421838
Stat Med. 2008 Jan 15;27(1):36-46
pubmed: 17634969
Circulation. 2016 Apr 5;133(14):e506-74
pubmed: 26399663
Pacing Clin Electrophysiol. 2016 Jun;39(6):588-91
pubmed: 27000950
Am J Cardiol. 2002 May 1;89(9):1120-3
pubmed: 11988206
Europace. 2014 Dec;16(12):1821-7
pubmed: 24919538
Lancet. 2017 Jul 8;390(10090):169-177
pubmed: 28077232
Eur Heart J. 2020 Feb 1;41(5):655-720
pubmed: 31504425
Eur Heart J. 2017 May 01;38(17):1317-1326
pubmed: 28329395
Arq Bras Cardiol. 2017 Apr;108(4):304-314
pubmed: 28538760
JAMA Intern Med. 2013 Nov 11;173(20):1863-71
pubmed: 24043208
Am J Cardiol. 2010 Aug 1;106(3):374-7
pubmed: 20643248
J Cardiovasc Pharmacol Ther. 2007 Jun;12(2):137-44
pubmed: 17562784
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
J Am Coll Cardiol. 2003 Sep 17;42(6):1103-7
pubmed: 13678938
Acad Emerg Med. 2002 Mar;9(3):203-8
pubmed: 11874776
Europace. 2017 Mar 1;19(3):465-511
pubmed: 27856540
Am J Cardiol. 1999 Aug 15;84(4):471-3, A9
pubmed: 10468092
Europace. 2017 Apr 01;19(4):602-606
pubmed: 28431060
Scand Cardiovasc J. 2017 Dec;51(6):299-307
pubmed: 29029561
Emerg Med J. 2014 Nov;31(11):872-6
pubmed: 25016388
J Eval Clin Pract. 2018 Jun;24(3):655-665
pubmed: 29194876
Arch Intern Med. 1997 Mar 10;157(5):537-43
pubmed: 9066458
Cardiol J. 2017;24(6):642-648
pubmed: 28541600
J Am Coll Dent. 2014 Summer;81(3):14-8
pubmed: 25951678
Ann Intern Med. 2000 Dec 5;133(11):864-76
pubmed: 11103056
J Emerg Med. 2018 Jul;55(1):1-6
pubmed: 29776700
J Eval Clin Pract. 2001 May;7(2):97-107
pubmed: 11489035